乌司他丁对重症急性胰腺炎患者肠道黏膜屏障功能的影响

目的：观察乌司他丁对重症急性胰腺炎患者肠道黏膜屏障功能的影响。方法：将57例急性重症胰腺炎患者随机分为治疗组（29例）和对照组（28例）。两组患者治疗过程中监测其血浆D-乳酸水平、尿乳果糖/甘露醇（L/M）值,观察重症胰腺炎患者ARDS、MODS发生率的情况。两组均给予常规治疗。治疗组在此基础上联合乌司他丁治疗,分别观察两组患者治疗后第7天、14天D-乳酸水平、L/M值的变化。结果：治疗7 d及14 d后,治疗组较对照组D-乳酸水平均明显降低（6.02±1.01）μg/L vs（8.86±0.75）μg/L、（3.77±0.82）μg/L vs（7.20±0.91）μg/L]（P〈0.01）;治疗14 d后,较对照组尿L/M值水平明显降低（0.048 0 vs 0.071 3）（P〈0.05）。治疗结束后,治疗组ARDS及MODS发生率较对照组均有显著降低（17.2%vs 50.0%、0 vs 25.0%）（P〈0.01）;治疗组较对照组28 d病死率明显降低（10.3%vs 32.1%）（P〈0.05）。结论：乌司他丁能改善重症急性胰腺炎患者肠道黏膜屏障功能,降低肠道细菌、内毒素移位,并能降低重症急性胰腺炎患者ARDS、MODS的发生率及28 d病死率。

Effect of Ulinastatin on the intestinal mucosal barrier function in patients with severe acute pancreatitis

Objective: To observe the effect of Ulinastatin on the intestinal mucosal barrier function in patients with severe acute pancreatitis.Methods: 58 cases of severe acute pancreatitis were randomly divided into treatment group(29 cases) and control group(28 cases).During treatment,the level of plasma D-lactic acid,urinary Lactulose/Mannitol(L/M) values were detected,ARDS and MODS incidence rate were observed in patients.Both groups were given to conventional treatment.Treatment group was added with Ulinastatin...